Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Total Non-Current Liabilities: 2019-2024

Historic Total Non-Current Liabilities for Revolution Medicines (RVMD) over the last 6 years, with Dec 2024 value amounting to $289.9 million.

  • Revolution Medicines' Total Non-Current Liabilities rose 234.70% to $649.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $649.1 million, marking a year-over-year increase of 234.70%. This contributed to the annual value of $289.9 million for FY2024, which is 26.60% up from last year.
  • As of FY2024, Revolution Medicines' Total Non-Current Liabilities stood at $289.9 million, which was up 26.60% from $229.0 million recorded in FY2023.
  • In the past 5 years, Revolution Medicines' Total Non-Current Liabilities registered a high of $289.9 million during FY2024, and its lowest value of $92.1 million during FY2020.
  • For the 3-year period, Revolution Medicines' Total Non-Current Liabilities averaged around $215.1 million, with its median value being $229.0 million (2023).
  • In the last 5 years, Revolution Medicines' Total Non-Current Liabilities fell by 6.19% in 2022 and then skyrocketed by 81.11% in 2023.
  • Over the past 5 years, Revolution Medicines' Total Non-Current Liabilities (Yearly) stood at $92.1 million in 2020, then surged by 46.36% to $134.8 million in 2021, then dropped by 6.19% to $126.4 million in 2022, then skyrocketed by 81.11% to $229.0 million in 2023, then climbed by 26.60% to $289.9 million in 2024.